[1]王燕云a,初丽敏b,王 婵a,等.早期胃癌患者外周血CDH-17，RHBDD1 和miR-135 表达水平与临床病理特征的相关性研究[J].现代检验医学杂志,2022,37(05):18-22.[doi:10.3969/j.issn.1671-7414.2022.05.005]
　WANG Yan-yuna,CHU Li-minb,WANG Chana,et al.Correlation between the Expression Levels of CDH-17, RHBDD1 and miR-135 in Peripheral Blood and Clinicopathological Features in Patients with Early Gastric Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):18-22.[doi:10.3969/j.issn.1671-7414.2022.05.005]
点击复制

早期胃癌患者外周血CDH-17，RHBDD1 和miR-135 表达水平与临床病理特征的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年05期
页码:
18-22
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Correlation between the Expression Levels of CDH-17, RHBDD1 and miR-135 in Peripheral Blood and Clinicopathological Features in Patients with Early Gastric Cancer
文章编号:
1671-7414（2022）05-018-05
作者:
王燕云a; 初丽敏b; 王 婵a; 胡美红a; 杨 晓b; 贺丽珠b
石家庄市第三医院a. 消化内科；b. 老年病科, 石家庄 050000
Author(s):
WANG Yan-yuna;  CHU Li-minb;  WANG Chana;  HU Mei-honga;  YANG Xiaob;  HE Li-zhub
a.Department of Gastroenterology；b.Department of Geriatrics, the Third Hospital of Shijiazhuang City, Shijiazhuang 050000，China
关键词:
早期胃癌; 临床分期; 组织学分级; 肝肠- 钙黏连蛋白-17; 菱形结构域蛋白1; 微小核糖核酸-135
分类号:
R735.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.05.005
文献标志码:
A
摘要:
目的　探究早期胃癌患者外周血肝肠- 钙黏连蛋白-17（liver-intestine cadherin-17，CDH-17）、菱形结构域蛋白1（rhombic domain-containing protein 1，RHBDD1）和微小核糖核酸（micro RNA, miR）-135 表达水平与临床病理特征的相关性。方法　回顾性选取2018 年5 月～ 2021 年6 月石家庄市第三医院105 例早期胃癌患者作为观察组，另选取同期健康体检者60 例作为对照组，以酶联免疫吸附法（enzyme linked immunosorbent assay，ELISA）测定CDH-17 和RHBDD1 水平，实时荧光聚合酶链反应（real-time fluorescence PCR，RT-PCR）测定miR-135 表达，比较两组外周血CDH-17，RHBDD1 和miR-135 表达， 分析外周血CDH-17，RHBDD1 和miR-135 与早期胃癌及临床病理特征的关系，绘制受试者工作特征（receiver operating characteristic，ROC）曲线，评价外周血CDH-17，RHBDD1 和miR-135 对早期胃癌的诊断价值。结果　与对照组相比，观察组外周血CDH-17（72.41±20.14 pg/ml vs59.69±14.37pg/ml），RHBDD1（374.26±115.74 ng/ml vs 214.37±56.41ng/ml）和miR-135（3.87±1.26 vs 2.47±0.81）表达均升高，差异有统计学意义（t=4.304，10.032，7.736，均P ＜ 0.05）；Logistic 回归分析，结果显示外周血CDH-17[OR=11.497, 95%CI=7.415 ～ 17.825]，RHBDD1[OR=13.748，95%CI=9.827 ～ 19.234] 和miR-135[OR=11.654,95%CI=7.946 ～ 17.991] 表达为早期胃癌独立危险因素（Wald χ2=38.417, 33.771, 37.877, 均P ＜ 0.05）。外周血CDH-17，RHBDD1 和miR-135 表达对早期胃癌的诊断价值的ROC 曲线显示外周血CDH-17，RHBDD1 和miR-135 表达对早期胃癌的诊断价值的AUC 分别为0.736，0.903 和0.828。 应用Logistic 二元回归拟合，构建各指标联合诊断的AUC 为0.947；外周血CDH-17，RHBDD1 和miR-135 表达与临床分期、组织学分级有关（r=0.625，0.631，0.657；-0.633，-0.625，-0.674，均P ＜ 0.05）。结论　早期胃癌患者外周血CDH-17，RHBDD1 和miR-135 表达明显上调，且与临床分期及组织学分级有关。临床可通过检测其水平，准确诊断早期胃癌，为临床治疗提供一定依据，对改善患者预后具有重要意义。
Abstract:
Objective　To explore the correlation between the levels of liver-intestine cadherin-17 (CDH-17), rhombic domain -containing protein 1 (RHBDD1) and miR-135 in peripheral blood and clinicopathological features in patients with early gastric cancer.Methods　From May 2018 to June 2021, 105 patients with early gastric cancer in the Third Hospital of Shijiazhuang City, were retrospectively selected as the observation group, and 60 patients with healthy physical examination during the same period were selected as the control group. To compare the expressions of CDH-17, RHBDD1and miR-135 in peripheral blood of the two groups, analyzed the relationship between CDH-17, RHBDD1and miR-135 in peripheral blood and early gastric cancer and clinicopathological characteristics. Drew receiver operating characteristic(ROC) curve, and evaluated peripheral the diagnostic value of blood CDH-17, RHBDD1 and miR-135 in early gastric cancer. Results　In the observation group, peripheral blood CDH-17 (72.41±20.14pg/ml vs 59.69±14.37pg/ml), RHBDD1 (374.26±115.74ng/ml vs 214.37±56.41ng/ml), miR-135 (3.87±1.26 vs 2. 47±0.81) expression was higher than the control group，the differences were statistically significant (t=4.304, 10.032, 7.736, all P ＜ 0.05). Logistic regression analysis showed that the expression of CDH-17[OR=11.497,95% CI=7.415 ～ 17.825], RHBDD1[OR=13.748,95%CI=9.827 ～ 19.234] and miR-135[OR=11.654, 95%CI=7.946 ～ 17.991] in peripheral blood were independent risk factors for early gastric cancer (Wald χ2=38.417, 33.771, 37.877, all P ＜ 0.05) . The ROC curve of the diagnostic value of peripheral blood CDH-17, RHBDD1 and miR-135 expression for early gastric cancer showed that the AUC of the peripheral blood CDH-17, RHBDD1and miR-135 expression for the diagnostic value of early gastric cancer was 0.736, 0.903 and 0.828,respectively . Logistic binary regression fitting to construct the AUC of each index combined diagnosis showed that the combined AUC of each index was 0.947. The expression of CDH-17, RHBDD1 and miR-135 in peripheral blood was related to clinical stage and histological grade (r=0.625, 0.631, 0.657；-0.633, -0.625 ，-0.674, all P ＜ 0.05). Conclusion　The expression of CDH-17, RHBDD1 and miR-135 in the peripheral blood of patients with early gastric cancer was significantly up-regulated, and was related to clinical staging and histological grading. The clinical level can be detected to accurately diagnose early gastric cancer, which can provide a basis for clinical treatment and improve patients. The prognosis is of great significance.

参考文献/References:

[1] JOHNSTON F M, BECKMAN M. Updates on management of gastric cancer[J]. Current Oncology Reports, 2019, 21(8): 67.
[2] 王静雷, 杨一兵, 耿云霞, 等.1990 ～ 2017 年中国胃癌发病、患病及死亡状况趋势分析[J]. 中国慢性病预防与控制, 2020, 28(5):321-325.
WANG Jinglei, YANG Yibing, GENG Yunxia, et al. Trend analysis of the morbidity, prevalence and mortality of stomach cancer in China from 1990 to 2017 [J]. Chinese Journal of Prevention and Control of Chronic Diseases,2020,28(5):321-325.
[3] SMYTH E C, NILSSON M, GRABSCH H I, et al.Gastric cance[J]. Lancet, 2020, 396(10251): 635-648.
[4] 刘亚倩, 汪天培, 颜财旺, 等. 多基因遗传风险评分与胃癌发病年龄的关联分析[J].中华流行病学杂志,2021, 42(6):1092-1096.
LIU Yaqian, WANG Tianpei, YAN Caiwang, et al.Association between polygenic risk score and age at onset of gastric cancer [J]. Chinese Journal of Epidemi ology,2021,42(6):1092-1096.
[5] MACHLOWSKA J, BAJ J, SITARZ M, et al. Gastric cancer: epidemiology, risk factors, classification,genomic characteristics and treatment strategies[J].International Journal of Molecular Sciences, 2020,21(11): 4012.
[6] 张力, 汤玮, 岳芙蓉, 等. 血清PG,G-17,CDH-17在胃癌中的表达及其诊断意义[J]. 实用癌症杂志,2020, 35(8):1258-1261.
ZHANG Li, TANG Wei, YUE Furong, et al. Expression and significance of serum PG,G-17 and CDH-17 in patients with gastric cancer [J]. The Practical Journal of Cancer, 2020, 35(8):1258-1261.
[7] 史济华, 徐雪, 崔海梦, 等. 血清菱形结构域蛋白、胃蛋白酶原和癌胚抗原对胃癌的早期诊断价值[J].基础医学与临床, 2019, 39(9):1316-1319.
SHI Jihua, XU Xue, CUI Haimeng, et al. Value of serum RHBDD1,pepsinogen and CEA in the early diagnosis of gastric cancer [J]. Basic and Clinical Medicine,2019,39(9):1316-1319.
[8] 文丝雨, 谭文华, 刘巍.microRNA-34a 在恶性肿瘤中的研究进展[J]. 中国临床研究, 2020, 33(10):1432-1434, 1438.
WEN Siyu, TAN Wenhua, LIU Wei. Research progress of microRNA-34a in malignant tumors [J]. Chinese Journal of Clinical Research,2020,33(10):1432-1434,1438.
[9] 王向阳, 余涛, 张静, 等. 胃癌胞外体中微小RNA-374a-5p 的表达及其临床意义[J]. 中华实验外科杂志,2021, 38(7):1336-1339.
WANG Xiangyang, YU Tao, ZHANG Jing, et al.Expression and clinical significance of microRNA-374a-5p in exosomes from gastric cancer [J]. Chinese Journal of Experimental Surgery,2021,38(7):1336-1339.
10] KUWADA K, KURODA S, KIKUCHI S, et al. Clinical impact of sarcopenia on Gastric cancer[J]. Anticancer Research, 2019, 39(5): 2241-2249.
[11] 杨之洵, 郑荣寿, 张思维, 等. 中国胃癌发病趋势及预测[J].中国肿瘤, 2019, 28(5): 321-326.
YANG Zhixun, ZHENG Rongshou, ZHANG Siwei, et al. Trend and prediction of stomach cancer incidence in China [J]. China Cancer,2019,28(5):321-326.
[12] FUJIWARA K, TSUJI A B, SUDO H, et al. (111)Inlabeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis[J]. Annals of Nuclear Medicine, 2020, 34(1): 13-23.
[13] 林雅, 林义, 杨幼萍, 等.TTF-1,Napsin A,CDx2,CK20和CDH17 在肺肠型腺癌的诊断价值[J].江苏医药,2020, 46（9）：920-923.
LIN Ya, LIN Yi, YANG Youping, et al. Value of TTF-1,Napsin A,CDx2,CK20,and CDH17 in diagnosis of secondary pulmonary enteric adenocarcinoma [J].Jiangsu Medical Journal,2020,46(9):920-923.
[14] 韩峥, 黄晓东, 刘蒙, 等. 那可丁通过下调钙黏素17及Wnt3a/β-catenin 信号通路抑制结肠癌SW480 细胞迁移[J]. 中国肿瘤生物治疗杂志, 2019, 26(10):1089-1094.
HAN Zheng, HUANG Xiaodong, LIU Meng, et al.Noscapine inhibits migration of colon cancer SW480 cells by down-regulating Wnt3a/β-catenin signaling pathway and cadherin 17 [J]. Chinese Journal of Cancer Biotherapy,2019,26(10):1089-1094.
[15] 赵宁, 马威.肝肠钙粘蛋白及肿瘤标志物联合检测对胃癌分期的评估价值及与临床病理特征的关系[J]. 河北医学, 2019, 25(9):1422-1426.
ZHAO Ning, MA Wei. Assessment value of combined detection of hepatointestinal calcoprotein and tumor markers in staging of gastric cancer and its relationship with clinicopathological features [J]. Hebei Medicine,2019,25(9):1422-1426.
[16] 伍毓强, 乐桂花, 黄文瑜.胃癌患者60 例血清及黏膜组织CK-18,CDH-17,CA724 与CEA 检测的临床价值[J]. 福建医药杂志, 2019, 41(1):19-22.
WU Yuqiang, LE Guihua, HUANG Wenyu. Clinic value of cytokeratin-18,cadherin-17,carbohydrate antigen724 and carcinoembryonic antigen in serum and mucosal tissues for 60 cases of gastric cancer [J].Fujian Medical Journal,2019,41(1):19-22.
[17] ZHANG Mengmeng, MIAO Fei, HUANG Rong, et al. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 22.
[18] 居红格, 李峰, 马俊兵, 等. 三阴型乳腺癌中RHBDD1 和EGFR 的表达及相关性分析[J]. 临床与实验病理学杂志, 2020, 36(4):396-400.
JU Hong ge, LI Feng, MA Junbing, et al. Expression of RHBDD1 and EGFR in triple negative breast cancer and their correlation[J]. Chinese Journal of Clinical and Experimental Pathology, 2020, 36(4): 396-400.
[19] MIAO Fei, ZHANG Mengmeng, ZHAO Yuechao, et al.RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer[J]. Oncotarget, 2017, 8(15): 25251-25260.
[20] 万佳慧, 王孝锦, 姜世君, 等.菱形体蛋白的研究进展[J]. 牡丹江医学院学报, 2019, 40(1): 98-101.
WAN Jiahui, WANG Xiaojin, JIANG Shijun, et al.Research progress of rhombohedral protein [J].Journal of Mudanjiang Medical University,2019,40(1):98-101.
[21] 刘小娟, 孙科.MiR-135b-5p 靶向KLF4 基因调控胃癌SGC-7901 细胞生物学行为的研究[J]. 胃肠病学和肝病学杂志, 2019, 28(6):614-619.
LIU Xiaojuan, SUN Ke. The miR-135b-5p targeting KLF4 gene regulates the biological behavior of gastric cancer SGC-7901 cells [J]. Chinese Journal of Gastroenterology and Hepatology,2019,28(6):614-619。 [22] 刘青, 邓慧敏, 周林涛, 等. 卵巢癌患者组织中miR-135b 的表达及临床意义[J]. 现代检验医学杂志,2019,34(2):32-34.
LIU Qing, DENG Huimin, ZHOU Lintao, et al.Expression and clinical significance of miR-135b in tissues of patients with ovarian cancer [J]. Journal of Modern Laboratory Medicine,2019,34(2):32-34.
[23] 冯燕枝, 张景臣, 刘薇. 三阴性乳腺癌中miR-135b,LZTS1 表达水平对评估新辅助化疗疗效的价值[J].热带医学杂志, 2020, 20(4):525-529, 566, 封2.
FENG Yanzhi, ZHANG Jingchen, LIU Wei. The relationships between the expression of miR-135b,LZTS1 in triple-negative breast cancer and the efficacy of neoadjuvant chemotherapy [J]. Journal of Tropical Medicine,2020,20(4):525-529,566, F2.
[24] 田雯, 陈珑, 马艳华, 等.血清miR-135 及miR-601在胃癌患者中的表达及其诊断价值[J]. 中国癌症杂志, 2020, 30(8):593-598.
TIAN Wen, CHEN Long, MA Yanhua, et al.Expressions of serum miR-135 and miR-601 and their diagnostic value in patients with gastric cancer[J].China Oncology, 2020, 30(8):593-598.

相似文献/References:

[1]李　辉,汪春新,秦明明,等.肺癌患者血清7项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究[J].现代检验医学杂志,2021,36(04):5.[doi:10.3969/j.issn.1671-7414.2021.04.002]
　LI Hui,WANG Chun-xin,QIN Ming-ming,et al.Study on the Application Value of Combined Detection of 7 Tumor Markersin Serum of Patients with Lung Cancer in Pathological Classificationand Clinical Staging[J].Journal of Modern Laboratory Medicine,2021,36(05):5.[doi:10.3969/j.issn.1671-7414.2021.04.002]
[2]潘国刚,杨碧秀.鼻咽癌不同临床分期中白细胞介素水平表达的最新研究进展[J].现代检验医学杂志,2021,36(05):184.[doi:10.3969/j.issn.1671-7414.2021.05.040]
　PAN Guo-gang,YANG Bi-xiu.Latest Research Progress on the Expression Mechanism of Interleukin inNasopharyngeal Carcinoma Different Clinical Staging[J].Journal of Modern Laboratory Medicine,2021,36(05):184.[doi:10.3969/j.issn.1671-7414.2021.05.040]

备注/Memo

备注/Memo:
基金项目：石家庄市科学技术研究与发展计划项目，编号：211461103。
作者简介：王燕云（1975-），女，硕士研究生，副主任医师，研究方向：消化道肿瘤及胃镜下治疗，E-mail:luchuanjunshd@163.com。
更新日期/Last Update: 2022-09-15